Sign inCreate account

Report workspace tools

NCT00954915TERMINATEDanonymous

A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis

Sponsor

Source record

MacroGenics

Phase

Source record

Phase 2a

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Psoriasis

Indication / condition

AI-normalized

Psoriasis

Intervention

Source record

teplizumab

Source & freshness

Source record

NCT ID

NCT00954915

Original source

ClinicalTrials.gov

Source last updated

Feb 10, 2022

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00954915

Title

A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis

Sponsor

MacroGenics

Status

TERMINATED

Phase

Phase 2a

Condition raw

Psoriasis

Condition normalized

Psoriasis

Modality raw

Psoriasis

Modality normalized

monoclonal antibody

Target raw

Psoriasis

Target normalized

Psoriasis

Interventions

teplizumab

Public preview

Source record

The study aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab, a monoclonal antibody, in adults with moderate to severe psoriasis. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00954915

Status

TERMINATED

Phase

Phase 2a

Sponsor

MacroGenics

Executive brief

Investment-Ready Snapshot

The study aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab, a monoclonal antibody, in adults with moderate to severe psoriasis. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 10, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00954915

Indication

Psoriasis

Modality

monoclonal antibody

Target

Psoriasis

Intervention

teplizumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.